Last reviewed · How we verify
The DR group
The DR group is a class of drugs that targets the renin-angiotensin system to lower blood pressure and reduce the risk of cardiovascular events.
The DR group is a class of drugs that targets the renin-angiotensin system to lower blood pressure and reduce the risk of cardiovascular events. Used for Hypertension, Heart failure.
At a glance
| Generic name | The DR group |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Angiotensin receptor blocker (ARB) |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The DR group works by blocking the action of angiotensin II, a potent vasoconstrictor, which leads to vasodilation and a decrease in blood pressure. This class of drugs is often used to treat hypertension and heart failure.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure (NA)
- Peer-led Psycho-education for Schizophrenia (NA)
- Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial (NA)
- Viromes in Infants Presenting With a Septic Syndrome (NA)
- Qnnections: Refinement and Pilot Trial of a Suicide Prevention Intervention to Increase Social Connection (NA)
- "Finding Solid Ground" in Inpatient Treatment for Dissociative Disorder Patients Followed by Transition to Outpatient Treatment Settings: A 1-year Follow-up Pilot Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The DR group CI brief — competitive landscape report
- The DR group updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI